Contribution of PET Imaging to Clinical Management of Gliomas
Abstract
Gliomas originating from glial cells comprise about 30% of all primary central nervous system tumors and 80% of malignant brain tumors. Gliomas differ in their biological activity and are categorized according to grades, from benign to malignant with high recurrence rates. For diagnosis, location and extent of the tumor is assessed by CT and MRI, but for grading, additional parameters are necessary: contrast enhanced CT and MRI reveal damage of the blood–brain barrier, perfusion-weighted MRI sho [...]